vitile mr 30 mg modified release tablets
actavis group ptc ehf - gliclazide - modified-release tablet - 30 milligram(s) - sulfonamides, urea derivatives; gliclazide - blood glucose lowering drugs, excl. insulins: sulfonylureas - non insulin-dependent diabetes (type 2) in adults when dietary measures, physical exercise and weight loss alone are not sufficient to control blood glucose.
azildor 30mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - gliclazide - modified-release tablet - gliclazide 30 mg - drugs used in diabetes
azildor 60mg
actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - gliclazide - modified-release tablet - gliclazide 60 mg - drugs used in diabetes
gliclazide sandoz retard 60 mg, tabletten met gereguleerde afgifte
gliclazide lupin mr gliclazide 60 mg modified release tablet blister pack
lupin australia pty limited - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: povidone; calcium hydrogen phosphate dihydrate; hypromellose; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
pharmacor gliclamiron gliclazide 60 mg modified release tablet blister pack
pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: sodium acetate; magnesium stearate; lactose monohydrate; silicon dioxide; mannitol; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
pharmacor gliclaron gliclazide 60 mg modified release tablet bottle pack
pharmacor pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; mannitol; silicon dioxide; hypromellose; magnesium stearate; sodium acetate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
pharmacor gliclaron gliclazide 30 mg modified release tablet bottle pack
pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; mannitol; sodium acetate; silicon dioxide; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
pharmacor gliclamiron gliclazide 30 mg modified release tablet bottle pack
pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: magnesium stearate; hypromellose; sodium acetate; silicon dioxide; mannitol; lactose monohydrate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
pharmacor gliclaron gliclazide 30 mg modified release tablet blister pack
pharmacor pty ltd - gliclazide, quantity: 30 mg - tablet, modified release - excipient ingredients: hypromellose; mannitol; lactose monohydrate; sodium acetate; silicon dioxide; magnesium stearate - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.,during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.